Allergan hikes profits forecast despite reform costs

Allergan (NYSE: AGN) reported better-than-expected first-quarter earnings on strong sales of its Botox anti-wrinkle drug; it slightly raised the low end of its 2010 profit forecast despite costs of U.S. healthcare reforms. Report